Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MARKSANS PHARMA. vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 MARKSANS PHARMA.   MYLAN
EQUITY SHARE DATA
    MARKSANS PHARMA.
Mar-23
MYLAN
Dec-18
MARKSANS PHARMA./
MYLAN
5-Yr Chart
Click to enlarge
High Rs743,975-   
Low Rs392,188-   
Sales per share (Unadj.) Rs40.91,829.1-  
Earnings per share (Unadj.) Rs5.949.7-  
Cash flow per share (Unadj.) Rs7.0392.1-  
Dividends per share (Unadj.) Rs0.500-  
Avg Dividend yield %0.90-  
Book value per share (Unadj.) Rs38.51,978.8-  
Shares outstanding (eoy) m453.16514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.41.7 82.1%   
Avg P/E ratio x9.762.0 15.6%  
P/CF ratio (eoy) x8.17.9 102.8%  
Price / Book Value ratio x1.51.6 94.3%  
Dividend payout %8.50-   
Avg Mkt Cap Rs m25,6311,585,442 1.6%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m2,3940-   
Avg. sales/employee Rs Th026,887.8-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.1-  
INCOME DATA
Net Sales Rs m18,521941,074 2.0%  
Other income Rs m5930-   
Total revenues Rs m19,115941,074 2.0%   
Gross profit Rs m3,393243,515 1.4%  
Depreciation Rs m519176,206 0.3%   
Interest Rs m9145,262 0.2%   
Profit before tax Rs m3,37722,047 15.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m723-3,507 -20.6%   
Profit after tax Rs m2,65325,554 10.4%  
Gross profit margin %18.325.9 70.8%  
Effective tax rate %21.4-15.9 -134.7%   
Net profit margin %14.32.7 527.5%  
BALANCE SHEET DATA
Current assets Rs m16,997525,495 3.2%   
Current liabilities Rs m3,654383,144 1.0%   
Net working cap to sales %72.015.1 476.3%  
Current ratio x4.71.4 339.2%  
Inventory Days Days684 6.8%  
Debtors Days Days8293 88.0%  
Net fixed assets Rs m5,246182,553 2.9%   
Share capital Rs m453501 90.4%   
"Free" reserves Rs m16,9980-   
Net worth Rs m17,4521,018,070 1.7%   
Long term debt Rs m01,098,825 0.0%   
Total assets Rs m22,2422,730,861 0.8%  
Interest coverage x38.01.5 2,554.7%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.80.3 241.6%   
Return on assets %12.32.6 475.8%  
Return on equity %15.22.5 605.7%  
Return on capital %19.93.2 625.0%  
Exports to sales %00-   
Imports to sales %7.30-   
Net fx Rs m5,1430-   
CASH FLOW
From Operations Rs m2,374195,555 1.2%  
From Investments Rs m-2,592-101,081 2.6%  
From Financial Activity Rs m1,978-91,101 -2.2%  
Net Cashflow Rs m1,7601,620 108.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare MARKSANS PHARMA. With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare MARKSANS PHARMA. With: NATURAL CAPS  HESTER BIOSCIENCES  COLINZ LABOR  KOPRAN.  PARENT.DRUGS  



Today's Market

Sensex Today Trades Lower | Nifty Below 22,150 | Vodafone Idea Falls 3%, TCS 2% Sensex Today Trades Lower | Nifty Below 22,150 | Vodafone Idea Falls 3%, TCS 2%(10:30 am)

Asian markets extended decline and traded lower on Tuesday ahead of key economic data from China and as geopolitical tension intensified in the Middle East.